Cargando…

The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers

BACKGROUND: To identifying the effects of DNA methylation and epigenetic factors on the expression of CD133, a cancer stem cell marker, in gynecologic cancer cell lines. METHODS: Ovarian cancer cell lines (OVCAR-8 and IGROV-1) and an endometrial cancer cell line (Ishikawa) were treated with 5-aza-2`...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Kyung-Jin, So, Kyeong A, Ouh, Yung-Taek, Hong, Jin-Hwa, Lee, Jae-Kwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489563/
https://www.ncbi.nlm.nih.gov/pubmed/23067401
http://dx.doi.org/10.1186/1757-2215-5-28
_version_ 1782248741844025344
author Min, Kyung-Jin
So, Kyeong A
Ouh, Yung-Taek
Hong, Jin-Hwa
Lee, Jae-Kwan
author_facet Min, Kyung-Jin
So, Kyeong A
Ouh, Yung-Taek
Hong, Jin-Hwa
Lee, Jae-Kwan
author_sort Min, Kyung-Jin
collection PubMed
description BACKGROUND: To identifying the effects of DNA methylation and epigenetic factors on the expression of CD133, a cancer stem cell marker, in gynecologic cancer cell lines. METHODS: Ovarian cancer cell lines (OVCAR-8 and IGROV-1) and an endometrial cancer cell line (Ishikawa) were treated with 5-aza-2`-deoxycytidine (DAC) or Trichostatin A (TSA). Expression of CD133 was evaluated by quantitative real-time PCR, methylation-specific PCR (MSP), reverse transcription-PCR, western blot, and FACS analysis. All results are representative of three independent experiments. RESULTS: CD133 mRNA expression varied among the different cell lines; the weakest expression was observed in OVCAR-8 cells, while it was strongly expressed in Ishikawa cells. The degree of methylation of the CD133 P2 promoter was 61% in OVCAR-8 cells, 53% in IGROV-1 cells, and 43% in Ishikawa cells. CD133 expression was increased at both the mRNA and protein level after DAC treatment. On the contrary, CD133 mRNA expression decreased after TSA treatment decreased in all cell lines except OVCAR-8. In addition, MSP of the CD133 P2 promoter revealed that methylation was reduced after treatment with either DAC or TSA. CONCLUSIONS: The expression of the CD133 antigen in primary ovarian and endometrial cancer cell lines is regulated by epigenetics, as indicated by its increased expression following DAC treatment and irregular expression pattern followed by TSA treatment. In addition, the expression of CD133 was negatively correlated with the degree of methylation of the CD133 P2 promoter.
format Online
Article
Text
id pubmed-3489563
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34895632012-11-06 The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers Min, Kyung-Jin So, Kyeong A Ouh, Yung-Taek Hong, Jin-Hwa Lee, Jae-Kwan J Ovarian Res Research BACKGROUND: To identifying the effects of DNA methylation and epigenetic factors on the expression of CD133, a cancer stem cell marker, in gynecologic cancer cell lines. METHODS: Ovarian cancer cell lines (OVCAR-8 and IGROV-1) and an endometrial cancer cell line (Ishikawa) were treated with 5-aza-2`-deoxycytidine (DAC) or Trichostatin A (TSA). Expression of CD133 was evaluated by quantitative real-time PCR, methylation-specific PCR (MSP), reverse transcription-PCR, western blot, and FACS analysis. All results are representative of three independent experiments. RESULTS: CD133 mRNA expression varied among the different cell lines; the weakest expression was observed in OVCAR-8 cells, while it was strongly expressed in Ishikawa cells. The degree of methylation of the CD133 P2 promoter was 61% in OVCAR-8 cells, 53% in IGROV-1 cells, and 43% in Ishikawa cells. CD133 expression was increased at both the mRNA and protein level after DAC treatment. On the contrary, CD133 mRNA expression decreased after TSA treatment decreased in all cell lines except OVCAR-8. In addition, MSP of the CD133 P2 promoter revealed that methylation was reduced after treatment with either DAC or TSA. CONCLUSIONS: The expression of the CD133 antigen in primary ovarian and endometrial cancer cell lines is regulated by epigenetics, as indicated by its increased expression following DAC treatment and irregular expression pattern followed by TSA treatment. In addition, the expression of CD133 was negatively correlated with the degree of methylation of the CD133 P2 promoter. BioMed Central 2012-10-15 /pmc/articles/PMC3489563/ /pubmed/23067401 http://dx.doi.org/10.1186/1757-2215-5-28 Text en Copyright ©2012 Min et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Min, Kyung-Jin
So, Kyeong A
Ouh, Yung-Taek
Hong, Jin-Hwa
Lee, Jae-Kwan
The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers
title The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers
title_full The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers
title_fullStr The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers
title_full_unstemmed The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers
title_short The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers
title_sort effects of dna methylation and epigenetic factors on the expression of cd133 in ovarian cancers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489563/
https://www.ncbi.nlm.nih.gov/pubmed/23067401
http://dx.doi.org/10.1186/1757-2215-5-28
work_keys_str_mv AT minkyungjin theeffectsofdnamethylationandepigeneticfactorsontheexpressionofcd133inovariancancers
AT sokyeonga theeffectsofdnamethylationandepigeneticfactorsontheexpressionofcd133inovariancancers
AT ouhyungtaek theeffectsofdnamethylationandepigeneticfactorsontheexpressionofcd133inovariancancers
AT hongjinhwa theeffectsofdnamethylationandepigeneticfactorsontheexpressionofcd133inovariancancers
AT leejaekwan theeffectsofdnamethylationandepigeneticfactorsontheexpressionofcd133inovariancancers
AT minkyungjin effectsofdnamethylationandepigeneticfactorsontheexpressionofcd133inovariancancers
AT sokyeonga effectsofdnamethylationandepigeneticfactorsontheexpressionofcd133inovariancancers
AT ouhyungtaek effectsofdnamethylationandepigeneticfactorsontheexpressionofcd133inovariancancers
AT hongjinhwa effectsofdnamethylationandepigeneticfactorsontheexpressionofcd133inovariancancers
AT leejaekwan effectsofdnamethylationandepigeneticfactorsontheexpressionofcd133inovariancancers